XENE

Xenon Pharmaceuticals Inc.

Fundamental data last updated:November 14, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

CA

Next Earnings Date

Pending Announcement

Business Summary

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.

 


VALUATION

P/E

-8.26

Market Cap ($M USD)

$3.79B

Forward P/E

11.77

PEG

-0.99

PRICE TO SALES

0.00

PRICE TO BOOK

3.14

EV / EBITDA

-8.84

5-Year Average P/E

Free Cash Flow Yield

-8.92%

DCF Value

$2.44

Graham Number

N/A

Price to FCF

-11.21

EV to FCF

-10.87

Earnings Yield

-10.49%

FCF Yield

-8.92%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$4.11

Next Year EPS Growth Estimate

-$4.60

Next Year Revenue Growth Estimate

$1.44M

Return on Equity (ROE)

-43.98%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.01

Piotroski F-Score

2

Altman Z-Score

40.83

Return on Invested Capital (ROIC)

-35.10%

Current Ratio

21.02

Quick Ratio

21.02

Net Debt to EBITDA

0.27

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-3.40

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

Xenon Pharmaceuticals Inc. presents a perplexing valuation scenario. Despite a market cap exceeding $3.6 billion, the stock’s price has been trading significantly below its DCF value, suggesting potential undervaluation. However, the negative earnings yield and a Forward P/E of 11.77 indicate the market’s cautious optimism about future profitability. The Altman Z-score of 38.92 signals robust financial health, yet the negative ROIC and EPS raise red flags about operational efficiency. This juxtaposition of metrics paints a complex picture of both opportunity and risk.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, Xenon Pharmaceuticals is inherently positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's rapid tech evolution could enhance their R&D efficiency and speed to market. However, the company's current financial metrics suggest it may need to bolster its tech infrastructure to fully capitalize on these opportunities.

The Bull Case

For the value-driven investor, Xenon Pharmaceuticals offers intriguing prospects. The company's minimal debt, evidenced by a Debt/Equity ratio of just 0.005, provides a solid foundation for growth. Despite a low Piotroski F-Score of 2, the impressive Altman Z-score and high Current Ratio indicate financial resilience. While the ROIC is negative, the potential for high sales growth next year could signal a turnaround, making it a speculative buy for those betting on future profitability.

The Bear Case

Xenon Pharmaceuticals faces significant structural challenges. The negative Price to FCF and FCF Yield highlight a troubling cash flow situation, exacerbated by an EPS projected to decline further next year. The stock's proximity to its 52-week high, coupled with a Price/Book ratio near 3, suggests it may be overvalued relative to its tangible assets. Investors should be wary of the company's inability to generate positive earnings, which could hinder its long-term viability.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$68.63

Institutional Ownership %

1-Year Beta

0.60

Insider Buying % (6 Mo)

Distance to 52-Week High

85.50%

Distance to 52-Week Low

14.78%

EARNINGS SURPRISE %

2.63%

50-DAY SMA

$43.04

200-DAY SMA

$52.30

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.